Scholarlink

Introduction <p>The long-acting injectable antipsychotic aripiprazole lauroxil (AL) can be initiated in a single day using a one-time injection of a NanoCrystal Dispersion formulation of AL (AL<sub>NCD</sub>) and a 30-mg oral dose of aripiprazole. Treatment with AL initiated using AL<sub>NCD</sub> significantly improved symptoms of schizophrenia in a phase 3b study. The current study evaluated real-world treatment patterns and healthcare resource utilization (HCRU) among patients with schizophrenia who initiated AL using AL<sub>NCD</sub>.</p> Methods <p>This retrospective analysis used data from January 1, 2018, to December 31, 2022, derived from Komodo’s Healthcare Map™, an administrative claims database. Adults with schizophrenia who initiated AL using AL<sub>NCD</sub> and had continuous enrollment&#xa0;≥&#xa0;6 months before (baseline) and after (follow-up) initiation were eligible. Treatment patterns were evaluated for 6&#xa0;months after initiation. Inpatient admissions, emergency department (ED) visits, and outpatient visits were compared before and after AL initiation using AL<sub>NCD</sub>.</p> Results <p>Patients who initiated AL using AL<sub>NCD</sub> in this study (<i>n</i>&#xa0;=&#xa0;1152) had a mean age of 38.4&#xa0;years; 35.9% were female. For most patients, their first AL dose was 1064&#xa0;mg (39.4%) or 882 mg (37.1%); 90.3% received their first AL injection along with AL<sub>NCD</sub> on the same day. A total of 898 (78.0%) patients subsequently received a second AL dose at any time during follow-up. Proportions of patients with all-cause, mental health (MH)-related, and schizophrenia-related inpatient admissions and ED visits significantly decreased between baseline and follow-up (all <i>P</i>&#xa0;&lt;&#xa0;0.001). Proportions of patients with all-cause, MH-related, and schizophrenia-related outpatient visits did not change, whereas the mean number of outpatient visits for each HCRU category increased significantly from baseline to follow-up (all <i>P</i>&#xa0;≤&#xa0;0.007).</p> Conclusions <p>Findings from this real-world study suggest that use of AL initiated with AL<sub>NCD</sub> results in significant declines in acute HCRU.</p>

错误：搜索内容不能为空，请输入英文关键词
错误：关键词超出字数限制，请精简
高级检索

Treatment Patterns and Healthcare Resource Utilization Following Initiation of Aripiprazole Lauroxil Using a 1-Day Initiation Regimen in Patients with Schizophrenia

  • 期刊论文

  • 出版模式：

    开放获取

  • 发表日期：

    2025年6月25日

查看全文
  • John Lauriello,
  • Michael J. Doane,
  • James A. McGrory,
  • Alejandro G. Hughes,
  • Lauren N. Strand

摘要

Introduction

The long-acting injectable antipsychotic aripiprazole lauroxil (AL) can be initiated in a single day using a one-time injection of a NanoCrystal Dispersion formulation of AL (ALNCD) and a 30-mg oral dose of aripiprazole. Treatment with AL initiated using ALNCD significantly improved symptoms of schizophrenia in a phase 3b study. The current study evaluated real-world treatment patterns and healthcare resource utilization (HCRU) among patients with schizophrenia who initiated AL using ALNCD.

Methods

This retrospective analysis used data from January 1, 2018, to December 31, 2022, derived from Komodo’s Healthcare Map™, an administrative claims database. Adults with schizophrenia who initiated AL using ALNCD and had continuous enrollment ≥ 6 months before (baseline) and after (follow-up) initiation were eligible. Treatment patterns were evaluated for 6 months after initiation. Inpatient admissions, emergency department (ED) visits, and outpatient visits were compared before and after AL initiation using ALNCD.

Results

Patients who initiated AL using ALNCD in this study (n = 1152) had a mean age of 38.4 years; 35.9% were female. For most patients, their first AL dose was 1064 mg (39.4%) or 882 mg (37.1%); 90.3% received their first AL injection along with ALNCD on the same day. A total of 898 (78.0%) patients subsequently received a second AL dose at any time during follow-up. Proportions of patients with all-cause, mental health (MH)-related, and schizophrenia-related inpatient admissions and ED visits significantly decreased between baseline and follow-up (all P < 0.001). Proportions of patients with all-cause, MH-related, and schizophrenia-related outpatient visits did not change, whereas the mean number of outpatient visits for each HCRU category increased significantly from baseline to follow-up (all P ≤ 0.007).

Conclusions

Findings from this real-world study suggest that use of AL initiated with ALNCD results in significant declines in acute HCRU.